Literature DB >> 3084654

A secreted form of the human interleukin 2 receptor encoded by an "anchor minus" cDNA.

B F Treiger, W J Leonard, P Svetlik, L A Rubin, D L Nelson, W C Greene.   

Abstract

The DNA sequence encoding all of the putative intracytoplasmic domain and most of the trans-membrane domain of the human IL 2 receptor was deleted from a full length receptor cDNA. After expression in mouse L cells, the resultant "anchor minus" cDNA was found to direct the synthesis of a secreted rather than membrane-associated form of the IL 2 receptor. The secreted receptor protein (44,000 to 46,000 Mr) retained the capacity to bind both IL 2 and the monoclonal anti-Tac antibody, as evidenced by retention on IL 2 and anti-Tac affinity columns, inhibition of [3H]-anti-Tac binding to HUT 102B2 cells, and partial inhibition of IL 2-induced CTLL proliferation. Removal of these domains from the IL 2 receptor did not alter the posttranslational processing or rate of export of the truncated receptor protein. These data confirm the proposed membrane orientation of the IL 2 receptor (NH2 terminus out, COOH terminus in) and underscore the anchoring function of this carboxy terminal receptor segment. The availability of such anchor minus receptor cDNA constructs may facilitate purification of large quantities of receptor protein for further analysis of receptor structure, valency, and localization of the IL 2 binding site(s).

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3084654

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  12 in total

1.  Relations between surface expression of the interleukin-2 receptor and release of the soluble form of the receptor in cultured mononuclear cells from patients with rheumatoid arthritis or systemic lupus erythematosus.

Authors:  M Itoh; Y Goto; Y Ohta; Y Goto; H Ohashi
Journal:  Clin Rheumatol       Date:  1998       Impact factor: 2.980

2.  Soluble IL-2Rα facilitates IL-2-mediated immune responses and predicts reduced survival in follicular B-cell non-Hodgkin lymphoma.

Authors:  Zhi-Zhang Yang; Deanna M Grote; Steven C Ziesmer; Michelle K Manske; Thomas E Witzig; Anne J Novak; Stephen M Ansell
Journal:  Blood       Date:  2011-06-30       Impact factor: 22.113

3.  Serum immunomodulatory factors in gastrointestinal diseases. A 30-50-kD serum fraction in Crohn's disease capable of modulating lymphocyte activation.

Authors:  L Biancone; M Boirivant; S Fais; G L Ricci; R Paganelli; F Pallone
Journal:  Clin Exp Immunol       Date:  1991-03       Impact factor: 4.330

4.  The transmembrane anchor of the T-cell antigen receptor beta chain contains a structural determinant of pre-Golgi proteolysis.

Authors:  T Wileman; G R Carson; F F Shih; M F Concino; C Terhorst
Journal:  Cell Regul       Date:  1990-11

Review 5.  Exploring the Pathogenic Role and Therapeutic Implications of Interleukin 2 in Autoimmune Hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2020-08-24       Impact factor: 3.199

6.  A soluble, high-affinity, interleukin-4-binding protein is present in the biological fluids of mice.

Authors:  R Fernandez-Botran; E S Vitetta
Journal:  Proc Natl Acad Sci U S A       Date:  1990-06       Impact factor: 11.205

7.  Constitutive secretion of soluble interleukin-2 receptor by human T cell lymphoma xenografted into SCID mice. Correlation of tumor volume with concentration of tumor-derived soluble interleukin-2 receptor in body fluids of the host mice.

Authors:  M A Wasik; N Sioutos; M Tuttle; J R Butmarc; W D Kaplan; M E Kadin
Journal:  Am J Pathol       Date:  1994-05       Impact factor: 4.307

8.  The IL-2/CD25 pathway determines susceptibility to T1D in humans and NOD mice.

Authors:  Calliope A Dendrou; Linda S Wicker
Journal:  J Clin Immunol       Date:  2008-09-09       Impact factor: 8.317

9.  Pharmacokinetics of recombinant human interleukin-2 in advanced renal cell carcinoma patients following subcutaneous application.

Authors:  G I Kirchner; A Franzke; J Buer; W Beil; M Probst-Kepper; F Wittke; K Overmann; S Lassmann; R Hoffmann; H Kirchner; A Ganser; J Atzpodien
Journal:  Br J Clin Pharmacol       Date:  1998-07       Impact factor: 4.335

10.  Levels of soluble interleukin-2 receptors are predictive of response in patients treated with interleukin-2 and lymphokine-activated killer cells.

Authors:  E Paietta; D L Nelson; J Andersen; J P Dutcher; P H Wiernik
Journal:  Med Oncol       Date:  1995-06       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.